Curasight is focused on addressing the need for improved diagnose of breast cancer and building on its foundation of pioneering research and development within uPAR PET Imaging. Our clinical development efforts include a program to develop a first-in-class uPAR PET imaging ligand which is currently entering phase II. We believe that our uPAR PET ligands have the potential to provide physicians with improved non-invasive and cost-effective options to help diagnose and evaluate breast cancer disease